NCT00253331View on ClinicalTrials.gov

Lab Study of MQX-503 in Treatment of Raynaud's

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

September 30, 2005

Conditions
Raynaud DiseaseRaynaud Disease Secondary to SclerodermaRaynaud Secondary to Other Autoimmune Disease
Interventions
DRUG

topical organogel with nitroglycerin

Trial Locations (2)

21224

Johns Hopkins Bayview Medical Center, Baltimore

98195

University of Washington Medical College, Seattle

Sponsors
All Listed Sponsors
lead

MediQuest Therapeutics

INDUSTRY